Document is current
Any future updates will be listed below
-
Authors
Li, Keyu
Wang, Junke
Zhang, Rui
Zhou, Jiawei
Espinoza, Birginia
Niu, Nan
Wang, Jianxin
Jurcak, Noelle
Rozich, Noah
Osipov, Arsen
Henderson, MacKenzie
Funes, Vanessa
Lyman, Melissa
Blair, Alex B.
Herbst, Brian
He, Mengni
Yuan, Jialong
Trafton, Diego
Yuan, Chunhui
Wichroski, Michael
Liu, Xubao
Fu, Juan
Zheng, Lei
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82303740)
Science and Technology Department of Sichuan Province (2023YFS0167)
China Postdoctoral Science Foundation (2023T160451)
West China Hospital Postdoctoral Science Foundation (2023HXBH053)
Bristol-Myers Squibb (II-ON grant)
National Institutes of Health (R01 CA169702, CA197296)
- License Information
-
More Information
Article History
Received: 8 May 2024
Accepted: 15 July 2024
First Online: 7 August 2024
Declarations
:
: All studies and maintenance of mice were conducted in accordance with the approval of the Institutional Animal Care and Use Committee (IACUC) guidelines of Johns Hopkins School of Medicine (Animal Protocol: MO22M59).
: Not applicable.
: L.Z. receives grant support from Bristol-Meyer Squibb, Merck, AstraZeneca, iTeos, Amgen, NovaRock, Inxmed, Halozyme and Abmeta. L.Z. is a paid consultant/Advisory Board Member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia/Xilio, QED, Novagenesis, Snow Lake Capitals, Amberstone, Pfizer, Tavotek, and Mingruizhiyao. L.Z. holds shares at Alphamab, Amberstone, Mingruizhiyao, and Cellaration. LZ is an editorial board member of Journal of Hematology and Oncology.
